Financhill
Sell
27

UCBJY Quote, Financials, Valuation and Earnings

Last price:
$139.07
Seasonality move :
7.29%
Day range:
$138.78 - $139.34
52-week range:
$71.16 - $151.76
Dividend yield:
0.57%
P/E ratio:
37.38x
P/S ratio:
7.26x
P/B ratio:
9.32x
Volume:
14K
Avg. volume:
20.5K
1-year change:
40.14%
Market cap:
$52.8B
Revenue:
$6.7B
EPS (TTM):
$3.81

Analysts' Opinion

  • Consensus Rating
    No consensus rating exists at this time due to lack of analyst coverage.
  • Price Target Downside
    No price target exists because of limited analyst coverage.
  • Price Target Upside
    Similarly, at this time, analysts have not provided a price target so downside risk can't be assessed accurately at this time.

Fair Value

  • According to the consensus of 0 analysts, UCB SA has -- downside to fair value with a price target of -- per share.

UCBJY vs. S&P 500

  • Over the past 5 trading days, UCB SA has underperformed the S&P 500 by -0.83% suggesting its relative strength compared to the major market average is weak at this time.

Share Buyback

  • UCB SA does not have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.

Revenue Growth

  • UCB SA has grown year-over-year revenues for 0 quarters straight. In the most recent quarter UCB SA reported revenues of --.

Earnings Growth

  • UCB SA has grown year-over-year earnings for 0 quarters straight. In the most recent quarter UCB SA reported earnings per share of --.
Enterprise value:
52.6B
EV / Invested capital:
--
Price / LTM sales:
7.26x
EV / EBIT:
39.62x
EV / Revenue:
7.07x
PEG ratio (5yr expected):
0.12x
EV / Free cash flow:
45.12x
Price / Operating cash flow:
46.33x
Enterprise value / EBITDA:
26.06x
Gross Profit (TTM):
$5.2B
Return On Assets:
7.93%
Net Income Margin (TTM):
19.43%
Return On Equity:
13.88%
Return On Invested Capital:
10.75%
Operating Margin:
--
Trailing 12 Months Fiscal Quarters
Period Ending 2010-12-31 2011-12-31 2012-12-31 2011-12-31 2012-12-31
Income Statement
Revenue $4.3B $4.5B $4.5B -- --
Gross Profit $2.9B $3.1B $3.1B -- --
Operating Income $620.6M $591.1M $572.7M -- --
EBITDA $958M $933.3M $869.2M -- --
Diluted EPS $0.33 $0.83 $0.90 -- --
Period Ending 2021-06-30 2022-06-30 2023-06-30 2024-06-30 2025-06-30
Balance Sheet
Current Assets $3.5B $3.4B $3.3B $3.6B $6.2B
Total Assets $15.5B $17B $16.7B $16.8B $20.2B
Current Liabilities $2.8B $3B $2.9B $3B $4.6B
Total Liabilities $6.4B $7.7B $6.9B $7.2B $8.8B
Total Equity $9.1B $9.3B $9.8B $9.6B $11.4B
Total Debt -- -- -- -- --
Trailing 12 Months Fiscal Quarters
Period Ending 2023-12-29 2024-12-29 2024-12-29
Cash Flow Statement
Cash Flow Operations -- -- -- -- --
Cash From Investing -- -- -- -- --
Cash From Financing -- -- -- -- --
Free Cash Flow -- -- -- -- --
UCBJY
Sector
Market Cap
$52.8B
$28.2M
Price % of 52-Week High
91.64%
50.25%
Dividend Yield
0.57%
0%
Shareholder Yield
1.15%
-1.54%
1-Year Price Total Return
40.14%
-18.1%
Beta (5-Year)
0.675
0.516
Dividend yield:
0.57%
Annualized payout:
$0.73
Payout ratio:
-19.96%
Growth streak:
0 years

Technicals

8-day SMA
Sell
Level $139.58
200-day SMA
Buy
Level $111.85
Bollinger Bands (100)
Buy
Level 118.27 - 143.29
Chaikin Money Flow
Buy
Level 28.7K
20-day SMA
Sell
Level $140.30
Relative Strength Index (RSI14)
Buy
Level 50.76
ADX Line
Buy
Level 15.41
Williams %R
Neutral
Level -77.1768
50-day SMA
Buy
Level $137.14
MACD (12, 26)
Buy
Level 38.13
25-day Aroon Oscillator
Buy
Level 40
On Balance Volume
Neutral
Level 17.9K

Financial Scores

Buy
Altman Z-Score (Annual)
Level (4.1008)
Buy
CA Score (Annual)
Level (0.1406)
Buy
Beneish M-Score (Annual)
Level (-2.3834)
Buy
Momentum Score
Level (8)
Buy
Ohlson Score
Level (-2.0121)
Buy
Piotroski F Score (Annual)
Level (8)
--
Quality Ratio Score
Level (--)
--
Fundamental Score
Level (--)

Revenue Forecast

Earnings per Share Forecast

Company Profile

UCB SA engages in the research and development of biopharmaceuticals products. It offers medicinal products such as briviact, keppra, vimpat, neupro, cimzia, nootropil, xyrem, xyzal, and zyrtec. The company was founded by Emmanuel Janssen on January 18, 1928 and is headquartered in Brussels, Belgium.

Stock Forecast FAQ

In the current month, UCBJY has received 0 Buy ratings 0 Hold ratings, and 0 Sell ratings. The UCBJY average analyst price target in the past 3 months is --.

  • Where Will UCB SA Stock Be In 1 Year?

    According to analysts, the consensus estimate is that UCB SA share price will drop to -- per share over the next 12 months.

  • What Do Analysts Say About UCB SA?

    Analysts are divided on their view about UCB SA share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that UCB SA is a Sell and believe this share price will rise from its current level to --.

  • What Is UCB SA's Price Target?

    The price target for UCB SA over the next 1-year time period is forecast to be -- according to 0 Wall Street analysts, 0 of them rate the stock a Buy, 0 rate the stock a Sell, and 0 analysts rate the stock a Hold.

  • Is UCBJY A Buy, Sell Or Hold?

    According to Wall Street analysts, the consensus rating for UCB SA is a --. 0 of 0 analysts rate the stock a -- at this time.

  • How Can I Buy Shares Of UCBJY?

    You can purchase shares of UCB SA via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase UCB SA shares.

  • What Is The UCB SA Share Price Today?

    UCB SA was last trading at $139.07 per share. This represents the most recent stock quote for UCB SA. Yesterday, UCB SA closed at $139.07 per share.

  • How To Buy UCB SA Stock Online?

    In order to purchase UCB SA stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Popular

Is DocuSign Stock Undervalued?
Is DocuSign Stock Undervalued?

Digital signature software business DocuSign (NASDAQ:DOCU) has been struggling over…

Is SentinelOne Stock Undervalued?
Is SentinelOne Stock Undervalued?

Cybersecurity major SentinelOne (NYSE:S) has struggled over several years, delivering…

Is Broadcom Stock on Sale?
Is Broadcom Stock on Sale?

Chip and software maker Broadcom (NASDAQ:AVGO) has been among the…

Stock Ideas

Buy
59
Is NVDA Stock a Buy?

Market Cap: $4.6T
P/E Ratio: 65x

Buy
55
Is AAPL Stock a Buy?

Market Cap: $4T
P/E Ratio: 37x

Buy
61
Is GOOG Stock a Buy?

Market Cap: $3.8T
P/E Ratio: 39x

Alerts

Buy
72
GLTO alert for Dec 25

Galecto, Inc. [GLTO] is down 0% over the past day.

Sell
20
SMX alert for Dec 29

SMX (Security Matters) Plc [SMX] is down 9.8% over the past day.

Sell
11
CDNAF alert for Dec 25

Canadian Tire Corp. Ltd. [CDNAF] is down 0% over the past day.

THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS

Show me the best stock